Developer docs
API playgroundTry for free, no card

Search company profiles

Medexprim

Full company profile

uuid002bv5z

Namestring
Medexprim
Legal namestring
BC Platforms
Websiteurl
medexprim.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

BC Platforms is a privately held health data and analytics company founded in 1997 that provides AI-enabled platforms and a global real-world data network to pharmaceutical companies and healthcare organizations engaged in drug development, regulatory submission, and precision medicine research. The company addresses the fragmentation of multi-modal healthcare data — spanning clinical, genomic, imaging, and multi-omics sources — through an integrated portfolio of five core products: BC Unify (AI-driven data mastering that ingests, harmonizes, transforms, and enriches multi-modal data), BC Catalyst (a prompt-based precision medicine platform for cohort identification, biomarker discovery, and population health analysis), BC Image (AI-driven medical image extraction, de-identification, and processing with GDPR-compliant workflows), BC Mosaic (a trusted research environment hosted on AWS Marketplace), and BC Data (a curated global real-world data network spanning oncology, neurology, rare diseases, immunology, and other therapeutic areas). The underlying technology architecture is AI-enabled and federated, including federated machine learning integrated through a partnership with Flower Labs, enabling collaborative research across distributed data sources without centralizing patient data.

The commercial model combines enterprise platform licensing and subscriptions with annual billing (quote-based, not publicly disclosed), revenue-sharing programs in which the 150+ healthcare organization data partners share in monetization of contributed data, and scientific and technology consulting services for evidence generation and AI implementation. GTM is anchored in direct enterprise field sales targeting top 20 pharmaceutical companies and 150+ healthcare organizations, augmented by AWS Marketplace distribution for BC Mosaic and an event-driven demand-generation layer across industry conferences and webinars. The company meets EHDS and GDPR+ standards, supports 20+ FDA/EMA regulatory submissions, and operates with a global footprint skewed outside the US (greater than 90% of accessible patient data is non-US). No parent entity, external investor roster, or disclosed funding rounds appear in the source data despite 25+ years of operation.

Short descriptiontext

BC Platforms provides AI-enabled data platforms and a global real-world data network spanning 187M+ patients to pharmaceutical companies and healthcare organizations, supporting drug development, regulatory submissions, and precision medicine research across multi-modal clinical, genomic, and imaging data.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToulouse, France
HQ citystring
Toulouse
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
real-world data analytics, trusted research environments, clinical data harmonization, precision medicine platforms, AI drug development
Industry3 codes
PRIMARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Healthcare Real-World Data Analytics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Data Platform Licensing and Subscription
TypeSubscription Recurring
Description

BC Platforms provides its AI-driven data platforms (BC Unify, BC Catalyst, BC Image, BC Mosaic) as solutions to pharmaceutical companies and healthcare organizations. The business model involves licensing access to platforms and data services that help reduce development timelines, enable personalized therapies, and support regulatory submissions. The company emphasizes a trusted partner relationship with revenue-sharing programs for data partners.

bcplatforms.com
2Data Partner Revenue Sharing
TypeData Monetisation
Description

Healthcare organizations that contribute data to BC Platforms' global network participate in revenue-sharing programs. This creates a mutually beneficial ecosystem where data partners harmonize, anonymize, and commercialize their data while receiving a share of resulting value.

bcplatforms.com
3Scientific & Technology Consulting
TypeProfessional Services
Description

Expert consulting services for evidence generation, data integration, scalable analytics, and AI implementation support the core platform business and provide additional service revenue.

bcplatforms.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise licensing with customized pricing based on scope and requirements
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for pharmaceutical companies and healthcare organizations. Solutions are tailored to customer requirements including data access, platform capabilities, and support levels.

bcplatforms.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1BC Unify
Description

AI-driven, end-to-end data mastering platform that ingests, harmonizes, transforms, and enriches multi-modal data.

bcplatforms.com
+4 more records
Core offering1 text field

Medexprim provides AI-enabled software platforms and a global real-world data network that allow pharmaceutical companies and healthcare organizations to ingest, harmonize, analyze, and collaborate on multi-modal clinical, genomic, imaging, and multi-omics data across the drug development lifecycle. Its portfolio includes data mastering (BC Unify), precision medicine cohort discovery (BC Catalyst), medical image processing (BC Image), trusted research environments (BC Mosaic), and curated real-world datasets (BC Data), supplemented by scientific and technology consulting services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduces development timelines compared to typical real-world data research at this scale
+3 more records
Product overview1 text field

BC Platforms offers a unified platform-plus-modules architecture comprising five core AI-enabled products: BC Unify (AI-driven data mastering platform), BC Catalyst (prompt-based precision medicine/cohort discovery), BC Image (medical image processing), BC Mosaic (trusted research environment on AWS), and BC Data (global real-world data network). These integrated solutions work together to enable end-to-end data provisioning, analytics, and collaboration across the drug development lifecycle, from data harmonization through secure research environments to actionable insights.

Product and service6 records
1BC Unify
CategoryData Mastering Platform
Description

AI-driven, end-to-end data mastering platform that ingests, harmonizes, transforms, and enriches multi-modal data (clinical, EMRs, eCRFs, labs, multi-omics, imaging) to support advanced use cases across the drug development lifecycle for pharmaceutical and healthcare customers.

2BC Catalyst
CategoryPrecision Medicine Analytics
Description

AI-powered, prompt-based precision medicine platform for cohort building, biomarker discovery, and population health insights that makes complex genomic and real-world clinical data actionable across the drug lifecycle for pharmaceutical researchers.

3BC Image
CategoryMedical Imaging Platform
Description

AI-driven, end-to-end platform that automates medical image extraction, de-identification, and processing, streamlining workflows for large image datasets while maintaining GDPR compliance for pharmaceutical and clinical research users.

4BC Mosaic
CategoryTrusted Research Environment
Description

Trusted research environment (TRE) built for clinical, genomic, and multi-omics studies, enabling secure collaboration and analysis with regulatory-compliant audit trail, bioinformatics capacity, and data visualization tools; available on AWS Marketplace.

5BC Data
CategoryReal-World Data Network
Description

Global real-world data network providing curated datasets spanning clinical data, EMRs, eCRFs, labs, multi-omics, and imaging data across oncology, neurology, rare diseases, immunology, and other therapeutic areas for pharmaceutical and research customers.

6Scientific & Technology Consulting
CategoryProfessional Services
Description

Expert consulting services providing guidance on evidence generation, data integration, scalable analytics, and AI implementation across healthcare and life sciences for pharmaceutical companies and healthcare organizations.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeTechnology or Integration
Description

BC Platforms has signed a Strategic Collaboration Agreement with AWS to enhance the speed and scale of trusted research environments. The collaboration focuses on scaling secure, AI-powered research environments for healthcare and life sciences innovation. BC Mosaic is available on AWS Marketplace as part of this partnership.

Strategic tierSecondaryTypeTechnology or Integration
Description

BC Platforms partners with Flower Labs to enable federated machine learning across trusted research environments. The partnership integrates the Flower Framework within BC Platforms' TREs, allowing collaborative AI model training without centralizing data, enhancing privacy-preserving machine learning capabilities.

3University of British Columbia
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Academic research partnership for advancing healthcare research through multi-modal data collaboration.

bcplatforms.com
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Partnership with UK health data research organization to support research initiatives and data sharing.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

NHS trust partnership supporting research data collaboration and precision medicine initiatives.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Genomics data partnership contributing to the global data network for research purposes.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Biobank data partnership contributing to research-ready multi-modal data availability.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

NHS foundation trust partnership for research data collaboration and clinical studies support.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Leading French cancer research institute partnership for oncology data and precision medicine research.

10Uniklinikum Wurzburg
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

German university hospital partnership for clinical research data collaboration.

bcplatforms.com
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

French hospital partnership contributing to research data network.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Industry association partnership supporting technology and innovation ecosystem.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Tempus Labs
TypeBroad incumbent
Description

Tempus operates a large AI-enabled precision medicine data platform spanning clinical, genomic, and imaging data with deep pharma partnerships, broadly comparable to BC Platforms' data and AI capabilities. It is a significantly larger US-centric incumbent with broader oncology focus.

TypeDirect peer
Description

Owkin is a federated AI platform for healthcare and life sciences that enables collaborative model training without moving patient data, similar to BC Platforms' federated learning capabilities. It targets the same pharma R&D customers and is a direct competitor in privacy-preserving clinical/genomic AI.

TypeBroad incumbent
Description

Health Catalyst provides healthcare data and analytics infrastructure to providers and life sciences organizations, overlapping with BC Platforms' healthcare segment in anonymization, monetization, and research enablement. It is a broader incumbent serving health systems rather than specializing in pharma R&D.

TypeBroad incumbent
Description

IQVIA is a global leader in clinical research, real-world evidence, and healthcare data analytics, broadly competing with BC Platforms' pharma R&D and RWE offerings. It operates a much larger portfolio across the drug development lifecycle, including its own EDC/CTMS stack.

TypeDirect peer
Description

TriNetX operates a global real-world data network of healthcare organizations for clinical research and trial feasibility, closely comparable to BC Platforms' BC Data network. It serves pharma with harmonized EHR data and network-based cohort discovery, overlapping with BC Catalyst use cases.

TypeDirect peer
Description

DNAnexus provides a cloud-based genomics and multi-omics data platform with strong pharma adoption, comparable to BC Platforms' multi-omics data capabilities within BC Data and the bioinformatics capacity of BC Mosaic. Both serve genomics-driven pharma R&D workflows.

TypeBroad incumbent
Description

Flatiron Health provides oncology-specific real-world data and EHR-linked analytics for pharma and providers, overlapping with BC Platforms' oncology RWD and clinical data offerings within BC Data. It is a broader incumbent with deeper US oncology data assets.

TypeDirect peer
Description

Datavant provides health data connectivity and de-identification infrastructure enabling secure linking of clinical and research datasets, comparable to BC Platforms' data harmonization and de-identification capabilities within BC Unify and BC Image. It serves similar pharma and healthcare data partner ecosystems.

TypeBroad incumbent
Description

Medidata (Dassault Systèmes) provides clinical trial informatics including EDC, CTMS, and eCOA as part of a broader life sciences platform, overlapping with BC Platforms' clinical trial data capabilities in BC Mosaic. It is a much larger incumbent serving the same top-20 pharma customer base.

TypeDirect peer
Description

Lifebit offers a federated genomics and trusted research environment platform for life sciences, very comparable to BC Platforms' BC Mosaic TRE and federated learning architecture. Both target pharma and genomics research customers seeking secure, compliant cross-institution analysis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers15 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medexprim

Healthcare Real-World Data Analyticsmedexprim.com

BC Platforms provides AI-enabled data platforms and a global real-world data network spanning 187M+ patients to pharmaceutical companies and healthcare organizations, supporting drug development, regulatory submissions, and precision medicine research across multi-modal clinical, genomic, and imaging data.

What Medexprim does

BC Platforms is a privately held health data and analytics company founded in 1997 that provides AI-enabled platforms and a global real-world data network to pharmaceutical companies and healthcare organizations engaged in drug development, regulatory submission, and precision medicine research. The company addresses the fragmentation of multi-modal healthcare data — spanning clinical, genomic, imaging, and multi-omics sources — through an integrated portfolio of five core products: BC Unify (AI-driven data mastering that ingests, harmonizes, transforms, and enriches multi-modal data), BC Catalyst (a prompt-based precision medicine platform for cohort identification, biomarker discovery, and population health analysis), BC Image (AI-driven medical image extraction, de-identification, and processing with GDPR-compliant workflows), BC Mosaic (a trusted research environment hosted on AWS Marketplace), and BC Data (a curated global real-world data network spanning oncology, neurology, rare diseases, immunology, and other therapeutic areas). The underlying technology architecture is AI-enabled and federated, including federated machine learning integrated through a partnership with Flower Labs, enabling collaborative research across distributed data sources without centralizing patient data.

The commercial model combines enterprise platform licensing and subscriptions with annual billing (quote-based, not publicly disclosed), revenue-sharing programs in which the 150+ healthcare organization data partners share in monetization of contributed data, and scientific and technology consulting services for evidence generation and AI implementation. GTM is anchored in direct enterprise field sales targeting top 20 pharmaceutical companies and 150+ healthcare organizations, augmented by AWS Marketplace distribution for BC Mosaic and an event-driven demand-generation layer across industry conferences and webinars. The company meets EHDS and GDPR+ standards, supports 20+ FDA/EMA regulatory submissions, and operates with a global footprint skewed outside the US (greater than 90% of accessible patient data is non-US). No parent entity, external investor roster, or disclosed funding rounds appear in the source data despite 25+ years of operation.

Medexprim firmographics

Firmographics
Name
Medexprim
Legal name
BC Platforms
Website
https://medexprim.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
1–10 employees
Short description
BC Platforms provides AI-enabled data platforms and a global real-world data network spanning 187M+ patients to pharmaceutical companies and healthcare organizations, supporting drug development, regulatory submissions, and precision medicine research across multi-modal clinical, genomic, and imaging data.
Ownership category
akta.pro rank

Medexprim industry classification

Industry
Product category
Healthcare Real-World Data Analytics
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Real-world data analytics
  • Trusted research environments
  • Clinical data harmonization
  • Precision medicine platforms
  • AI drug development

Where Medexprim is headquartered

Location

Headquarters

HQ city
Toulouse
HQ country
France
HQ region
Europe

Markets served

Medexprim business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Data Platform Licensing and Subscription: BC Platforms provides its AI-driven data platforms (BC Unify, BC Catalyst, BC Image, BC Mosaic) as solutions to pharmaceutical companies and healthcare organizations. The business model involves licensing access to platforms and data services that help reduce development timelines, enable personalized therapies, and support regulatory submissions. The company emphasizes a trusted partner relationship with revenue-sharing programs for data partners.
  2. Data Partner Revenue Sharing: Healthcare organizations that contribute data to BC Platforms' global network participate in revenue-sharing programs. This creates a mutually beneficial ecosystem where data partners harmonize, anonymize, and commercialize their data while receiving a share of resulting value.
  3. Scientific & Technology Consulting: Expert consulting services for evidence generation, data integration, scalable analytics, and AI implementation support the core platform business and provide additional service revenue.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise licensing with customized pricing based on scope and requirements

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Medexprim product offering

Product offering

Core offering

Medexprim provides AI-enabled software platforms and a global real-world data network that allow pharmaceutical companies and healthcare organizations to ingest, harmonize, analyze, and collaborate on multi-modal clinical, genomic, imaging, and multi-omics data across the drug development lifecycle. Its portfolio includes data mastering (BC Unify), precision medicine cohort discovery (BC Catalyst), medical image processing (BC Image), trusted research environments (BC Mosaic), and curated real-world datasets (BC Data), supplemented by scientific and technology consulting services.

Product overview

BC Platforms offers a unified platform-plus-modules architecture comprising five core AI-enabled products: BC Unify (AI-driven data mastering platform), BC Catalyst (prompt-based precision medicine/cohort discovery), BC Image (medical image processing), BC Mosaic (trusted research environment on AWS), and BC Data (global real-world data network). These integrated solutions work together to enable end-to-end data provisioning, analytics, and collaboration across the drug development lifecycle, from data harmonization through secure research environments to actionable insights.

Differentiator

Problem solved

Functional benefit

Brands

  • BC Unify: AI-driven, end-to-end data mastering platform that ingests, harmonizes, transforms, and enriches multi-modal data.
  • BC Catalyst
  • BC Image
  • BC Mosaic
  • BC Data

Products and services

  • BC Unify AI-driven, end-to-end data mastering platform that ingests, harmonizes, transforms, and enriches multi-modal data (clinical, EMRs, eCRFs, labs, multi-omics, imaging) to support advanced use cases across the drug development lifecycle for pharmaceutical and healthcare customers.
  • BC Catalyst AI-powered, prompt-based precision medicine platform for cohort building, biomarker discovery, and population health insights that makes complex genomic and real-world clinical data actionable across the drug lifecycle for pharmaceutical researchers.
  • BC Image AI-driven, end-to-end platform that automates medical image extraction, de-identification, and processing, streamlining workflows for large image datasets while maintaining GDPR compliance for pharmaceutical and clinical research users.
  • BC Mosaic Trusted research environment (TRE) built for clinical, genomic, and multi-omics studies, enabling secure collaboration and analysis with regulatory-compliant audit trail, bioinformatics capacity, and data visualization tools; available on AWS Marketplace.
  • BC Data Global real-world data network providing curated datasets spanning clinical data, EMRs, eCRFs, labs, multi-omics, and imaging data across oncology, neurology, rare diseases, immunology, and other therapeutic areas for pharmaceutical and research customers.
  • Scientific & Technology Consulting Expert consulting services providing guidance on evidence generation, data integration, scalable analytics, and AI implementation across healthcare and life sciences for pharmaceutical companies and healthcare organizations.

Quantifiable outcome

  • Reduces development timelines compared to typical real-world data research at this scale
  • +3 more outcomes

Companies that use Medexprim

Customer profile

Named customers15 records

Segments2 records

Ideal customer profiles2 records

Medexprim technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature6 records

Medexprim partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, secondary and minor.

  • Amazon Web Services (AWS)coreTechnology or IntegrationBC Platforms has signed a Strategic Collaboration Agreement with AWS to enhance the speed and scale of trusted research environments. The collaboration focuses on scaling secure, AI-powered research environments for healthcare and life sciences innovation. BC Mosaic is available on AWS Marketplace as part of this partnership.
  • Flower LabssecondaryTechnology or IntegrationBC Platforms partners with Flower Labs to enable federated machine learning across trusted research environments. The partnership integrates the Flower Framework within BC Platforms' TREs, allowing collaborative AI model training without centralizing data, enhancing privacy-preserving machine learning capabilities.
  • University of British ColumbiasecondaryStrategic or Co-development PartnerAcademic research partnership for advancing healthcare research through multi-modal data collaboration.
  • Health Data Research UK (HDRUK)secondaryStrategic or Co-development PartnerPartnership with UK health data research organization to support research initiatives and data sharing.
  • Imperial College Healthcare NHS TrustsecondaryStrategic or Co-development PartnerNHS trust partnership supporting research data collaboration and precision medicine initiatives.
  • University of Tartu Estonian Genome CentersecondaryStrategic or Co-development PartnerGenomics data partnership contributing to the global data network for research purposes.
  • Medical University of Graz BiobanksecondaryStrategic or Co-development PartnerBiobank data partnership contributing to research-ready multi-modal data availability.
  • NHS University Hospital SouthamptonsecondaryStrategic or Co-development PartnerNHS foundation trust partnership for research data collaboration and clinical studies support.
  • Institut Gustave RoussysecondaryStrategic or Co-development PartnerLeading French cancer research institute partnership for oncology data and precision medicine research.
  • Uniklinikum WurzburgsecondaryStrategic or Co-development PartnerGerman university hospital partnership for clinical research data collaboration.
  • Hôpital FochsecondaryStrategic or Co-development PartnerFrench hospital partnership contributing to research data network.
  • Technology Industries of FinlandminorStrategic or Co-development PartnerIndustry association partnership supporting technology and innovation ecosystem.

Scale indicators7 records

Recent moves3 records

Expansion highlights5 records

Medexprim competitors and assessment

Company assessment

Broad incumbents

  • Tempus Labs: Tempus operates a large AI-enabled precision medicine data platform spanning clinical, genomic, and imaging data with deep pharma partnerships, broadly comparable to BC Platforms' data and AI capabilities. It is a significantly larger US-centric incumbent with broader oncology focus.
  • Health Catalyst: Health Catalyst provides healthcare data and analytics infrastructure to providers and life sciences organizations, overlapping with BC Platforms' healthcare segment in anonymization, monetization, and research enablement. It is a broader incumbent serving health systems rather than specializing in pharma R&D.
  • IQVIA: IQVIA is a global leader in clinical research, real-world evidence, and healthcare data analytics, broadly competing with BC Platforms' pharma R&D and RWE offerings. It operates a much larger portfolio across the drug development lifecycle, including its own EDC/CTMS stack.
  • Flatiron Health: Flatiron Health provides oncology-specific real-world data and EHR-linked analytics for pharma and providers, overlapping with BC Platforms' oncology RWD and clinical data offerings within BC Data. It is a broader incumbent with deeper US oncology data assets.
  • Medidata Solutions: Medidata (Dassault Systèmes) provides clinical trial informatics including EDC, CTMS, and eCOA as part of a broader life sciences platform, overlapping with BC Platforms' clinical trial data capabilities in BC Mosaic. It is a much larger incumbent serving the same top-20 pharma customer base.

Direct peers

  • Owkin: Owkin is a federated AI platform for healthcare and life sciences that enables collaborative model training without moving patient data, similar to BC Platforms' federated learning capabilities. It targets the same pharma R&D customers and is a direct competitor in privacy-preserving clinical/genomic AI.
  • TriNetX: TriNetX operates a global real-world data network of healthcare organizations for clinical research and trial feasibility, closely comparable to BC Platforms' BC Data network. It serves pharma with harmonized EHR data and network-based cohort discovery, overlapping with BC Catalyst use cases.
  • DNAnexus: DNAnexus provides a cloud-based genomics and multi-omics data platform with strong pharma adoption, comparable to BC Platforms' multi-omics data capabilities within BC Data and the bioinformatics capacity of BC Mosaic. Both serve genomics-driven pharma R&D workflows.
  • Datavant: Datavant provides health data connectivity and de-identification infrastructure enabling secure linking of clinical and research datasets, comparable to BC Platforms' data harmonization and de-identification capabilities within BC Unify and BC Image. It serves similar pharma and healthcare data partner ecosystems.
  • Lifebit: Lifebit offers a federated genomics and trusted research environment platform for life sciences, very comparable to BC Platforms' BC Mosaic TRE and federated learning architecture. Both target pharma and genomics research customers seeking secure, compliant cross-institution analysis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Medexprim social profiles

Digital presence

Medexprim compliance and trust

Trust signal

Compliance2 records

Medexprim financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medexprim leadership team

Management profile

Number of profiles

Medexprim subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Medexprim funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medexprim M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medexprim

What does Medexprim do?

Medexprim provides AI-enabled software platforms and a global real-world data network that allow pharmaceutical companies and healthcare organizations to ingest, harmonize, analyze, and collaborate on multi-modal clinical, genomic, imaging, and multi-omics data across the drug development lifecycle. Its portfolio includes data mastering (BC Unify), precision medicine cohort discovery (BC Catalyst), medical image processing (BC Image), trusted research environments (BC Mosaic), and curated real-world datasets (BC Data), supplemented by scientific and technology consulting services.

Is Medexprim a public or private company?

Medexprim is a private company. It is classified as unknown and is currently operating.

When was Medexprim founded?

Medexprim was founded in 1997. It employs 1 to 10 people.

Where is Medexprim based?

Medexprim is headquartered in Toulouse, France, in the Europe region.

How does Medexprim make money?

Three revenue lines are on record. Data Platform Licensing and Subscription is the primary driver. The others are data Partner Revenue Sharing and scientific & Technology Consulting.

Who are Medexprim's main competitors?

Broad incumbents on record are Tempus Labs, Health Catalyst, IQVIA, Flatiron Health and Medidata Solutions. Direct peers are Owkin, TriNetX, DNAnexus, Datavant and Lifebit.

Does Medexprim have an API?

No public API is recorded for Medexprim.

What industry is Medexprim in?

Medexprim's product category is Healthcare Real-World Data Analytics. Its primary akta.pro industry code is HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireReal World Data (RWD) Market Research Report 2026-2035: A $4.2+ Billion Market by 2030, Drioven by Electronic Health Record Adoption, AI-driven Analytics, Personalized Medicine, and Value-based CareThe Real World Data (RWD) market is projected to grow from $2.01 billion in 2025 to $4.21 billion by 2030, reflecting a compound annual growth rate of 15.8%, driven by regulatory acceptance of real-world evidence, personalized medicine, AI-driven analytics, and digital health infrastructure investments. Carelon Research launched its Carelon Real World Data dataset in January 2025, while BC Platforms acquired Medexprim in December 2023 to expand its clinical imaging and multi-modal healthcare data capabilities. North America held the largest market share in 2025, with Asia-Pacific expected to witness the fastest growth during the forecast period.GlobeNewswireReal World Data (RWD) Market Research Report 2026-2035: A $4.2+ Billion Market by 2030, Drioven by Electronic Health Record Adoption, AI-driven Analytics, Personalized Medicine, and Value-based CareResearchAndMarkets.com released its Real World Data Market Report 2026, projecting the market to grow from $2.01 billion in 2025 to $4.21 billion by 2030 at a CAGR of 15.8%, driven by EHR adoption, AI-driven analytics, personalized medicine, and value-based care initiatives. The report highlights key strategic moves including Carelon Research's January 2025 launch of its integrated RWD dataset merging claims and EHR data, and BC Platforms' December 2023 acquisition of Medexprim to strengthen clinical imaging capabilities. North America held the largest market share in 2025, while Asia-Pacific is expected to witness the fastest growth through 2030.YahooReal World Data (RWD) Market Research Report 2026-2035: A $4.2+ Billion Market by 2030, Drioven by Electronic Health Record Adoption, AI-driven Analytics, Personalized Medicine, and Value-based CareResearchAndMarkets.com published a market research report projecting the Real World Data (RWD) market to grow from $2.01 billion in 2025 to $2.34 billion in 2026 and reach $4.21 billion by 2030, driven by EHR adoption, AI-driven analytics, personalized medicine, and value-based care. The report highlights key industry players including Oracle Corporation, IQVIA Holdings Inc., ICON PLC, and Syneos Health Inc., as well as notable strategic moves such as Carelon Research's January 2025 launch of a new RWD dataset and BC Platforms' December 2023 acquisition of Medexprim. North America held the largest market share in 2025, while Asia-Pacific is expected to witness the fastest growth during the forecast period.GlobeNewswireBC Platforms Acquires Medexprim, Paving the Way for GlobalBC Platforms acquired Medexprim, a European real-world data company, to expand access to clinical and imaging data across Europe. Medexprim, with a footprint in France, Germany, and Spain, will integrate immediately, and BC Platforms aims to become a global leader in real-world data.YahooBC Platforms Acquires Medexprim, Paving the Way for Global Leadership in Real-World Data and Real-World Evidence AnalyticsBC Platforms acquired Medexprim, a European real-world data company, to expand access to clinical and imaging data across Europe. Medexprim, with 35 experts in France and Paris, focuses on oncology, neurology, cardiology, and rare diseases. The companies will integrate immediately, with Medexprim's leadership joining BC Platforms' executive team.GlobeNewswireBC Platforms Acquires Medexprim, Paving the Way for GlobalBC Platforms acquired Medexprim, a European real-world data company, to expand access to clinical and imaging data across Europe. Medexprim, with 35 experts in France and Paris, focuses on oncology, neurology, cardiology, and rare diseases. The companies will integrate immediately, with Medexprim's leadership joining BC Platforms' executive team.FinSMEsBC Platforms Acquires MedexprimBC Platforms, a Zurich-based healthcare data management company, has acquired Medexprim, a Paris- and Toulouse-based real-world data firm. The undisclosed transaction aims to expand BC Platforms' capabilities in providing European biopharma partners with access to secure clinical and imaging data assets.DebiopharmBC Platforms Acquires Medexprim, Paving the Way for Global Leadership in Real-World Data and Real-World Evidence AnalyticsBC Platforms has acquired Medexprim, a European real-world data company with significant operations in France, Germany, and Spain. This acquisition expands BC Platforms' ability to provide biopharma partners with secure access to clinical and imaging data assets across the EU-5 countries. The move aims to establish BC Platforms as a global leader in real-world evidence analytics for precision medicine.PrwebClinerion and Medexprim join forces to combine clinical and imaging data for researchClinerion and Medexprim concluded a three-year partnership to merge electronic health records and imaging data into a private clinical data cloud for research. The joint offering provides de-identified, enriched longitudinal data points to improve research and patient care. The collaboration aims to expand hospital networks and implement a globally accessible clinical data warehouse.